Synapticure is a patient- and caregiver-founded virtual care provider offering nationwide access to expert neurologists, cutting-edge treatments and clinical trials, wraparound care coordination, and behavioral health support for neurodegenerative diseases. Since its launch in 2022 the company has grown to serve several thousand patients across the United States as a specialty virtual care platform for cognitive, neuromuscular, and movement disorders. Synapticure operates a single, standardized clinical operation across all 50 states, including in‑home research capacity, and was selected as a CMS GUIDE provider in all 50 states. The company reports it can provide appointments within two weeks and partners with ACOs, health systems, and health plans to lower costs and improve quality of life. Synapticure plans to use new funding to expand partnerships with providers and payers, invest in its proprietary technology platform (including AI-enabled analytics and remote monitoring), fast-track clinical research and trial enrollment, and scale its national medical group. Leadership and founding includes caregiver-advocates Sandra Abrevaya and Brian Wallach. Synapticure is a Chicago-based teleneurology company that provides personalized care for people living with ALS and their families. The company is building a full-stack teleneurology platform that provides access and continuity of care, including personalized care plans developed through testing, data analytics, and consultations with ALS specialists. It is collaborating with ALS clinics across the country, including Massachusetts General Hospital and University of California San Francisco. Founded by Brian Wallach and Sandra Abrevaya, Synapticure's team, board, and advisory board include clinicians and industry leaders across neurology, genetics, and health tech. Synapticure launched with $6M in seed funding and will use the capital to rapidly scale its care platform to people living with ALS across the United States.

Total raised

$31M

Funding rounds

2

Latest round

Series A

Latest activity

Nov 2024